Table 2.
Clinical and immunological data of subject included on the prospective study.
| Subject living within OEF (n = 212) | Subject living within NEF (n = 241) | Total (n = 453) | ||
|---|---|---|---|---|
| Age ≥ 6 years (n = 187) | Age < 6 years (n = 54) | |||
| Age, mean ± SD(min-max), year | 7.9 ± 1.5 (6–15) |
8.68 ± 1.42 (6–12) |
4.4 ± 0.66 (3–5) |
7.82 ± 1.9 (3–15) |
| Sex ratio (Male/Female) | 0.96 (104/108) | 0.85 (85/100) | 1.57 (33/21) | 0.96 (222/229) |
| ZCL scara | 60/212 | 36/186 | 9/54 | 105/452 |
| LSTb | 72/212 | 80/186 | 15/54 | 167/452 |
| Diameter of induration, mean ± SD | 3.6 ± 5.2 | 4.5 ± 4.5 | 3.45 ± 3.79 | 4 ± 4.82 |
| (min-max), mm | (0–31) | (0–15) | (0–13) | (0–31) |
LST, Leishmanin Skin Test;
a
Number of subject with scars/Total number of subject tested.
b
Number of subjects with positive LST/Total number of subject tested.
OEF, Old endemic foci; NEF, New endemic foci.